Citations

Clear

4847 citation(s) found for "Yu, Eric".

Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients
Lopez, Camden , Wolfe, Eric, Foster, Nathan R. , Mandrekar, Sumithra J. , Wang, Xiaofei , Adjei, Alex A. , Jatoi, Aminah , Adjei, Alex, Jatoi, Aminah , Lopez, Camden L , Le‐Rademacher, Jennifer , Kumar, Rajiv

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | September 17, 2020 | Volume: 11 | Issue: 6 | Pages: 1501-1508

10.1002/jcsm.12625 | PMID 32940014 Get It

AbstractBackgroundEligibility criteria and endpoints for cancer cachexia trials—and whether weight loss should be included—remain controversial. Although most cachexia trials enrol patients after initial cancer diagnosis, few studies have addressed whether weight loss well after a cancer diagnosis is prognostic.MethodsWe pooled data from non‐small cell lung cancer patients from prospectively conducted trials within the Alliance for Clinical Trials in Oncology (1998–2008), a nationally funded infrastructure. We examined (i) weight data availability and weight changes and (ii) survival.ResultsA total of 822 patients were examined. Of these, 659 (80%) were on treatment at the beginning of Cycle 2 of chemotherapy; weight was available for 656 (80%). By Cycles 3 and 4, weight was available for 448 (55%) and 384 (47%), respectively. From baseline to immediately prior to Cycle 2, 208 (32%) gained weight; 225 (34%) lost <2% of baseline weight; and 223 (34% of 656) lost 2% or more. Median survival from the beginning of Cycle 2 was 13.0, 10.9, and 6.9 months for patients with weight gain, weight loss of <2%, and weight loss of 2% or more, respectively. In multivariate analyses, adjusted for age, sex, performance score, type of treatment, and body mass index, weight loss of 2% or more was associated with poor overall survival compared with weight gain [hazard ratio (HR) = 1.66; 95% confidence interval (CI): 1.33–2.07; P < 0.001] and compared with weight loss of <2% (HR = 1.57; 95% CI: 1.27–1.95; P < 0.001). Although weight loss of <2% was not associated with poorer overall survival compared with weight gain, it was associated with poorer progression‐free survival (HR = 1.24; 95% CI: 1.01–1.51; P = 0.036). Similar findings were observed in a separate 255‐patient validation cohort.ConclusionsWeight should be integrated into cancer cachexia trials because of its ease of frequent measurement and sustained prognostic association.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Wu, David , Goodman, Aaron M. , Chadburn, Amy , Srkalović, Gordan , Leitch, Heather A. , Jayanthan, Raj , Schey, Steve , Oksenhendler, Éric , Lechowicz, Mary Jo , Hoffmann, Christian , Pemmaraju, Naveen , Bagg, Adam , Lim, Megan S. , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working, Wong, Raymond S M , Ferrero, Simone , Dispenzieri, Angela , Zinzani, Pier Luigi , van Rhee, Frits , Fajgenbaum, David C , Lim, Megan S , Wong, Raymond , Nasta, Sunita , Mukherjee, Sudipto , Ferrero, Simone , Sato, Yasuharu , Dispenzieri, Angela , Zinzani, Pier Luigi , Fosså, Alexander , Rhee, Frits van , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working

Mayo Clinic

American Journal of Hematology | September 16, 2020 | Volume: 95 | Issue: 12 | Pages: 1553-1561

10.1002/ajh.25992 | PMID 32894785 Get It

AbstractIdiopathic multicentric Castleman disease (iMCD) is a rare immunologic disorder characterized by systemic inflammation, multicentric lymphadenopathy, and organ dysfunction. Enlarged lymph nodes demonstrate a spectrum of characteristic but variable histopathologic features historically categorized into hyaline vascular (HV) (or hypervascular [HyperV] more recently), plasmacytic, or “mixed.” Though the etiology is unknown, a pro‐inflammatory cytokine storm, often involving interleukin‐6 (IL‐6), contributes to pathogenesis. Anti‐IL‐6 therapy with siltuximab is the only FDA‐ or EMA‐approved treatment based on efficacy and safety in multiple studies. Importantly, no patients considered to have HV histopathology achieved the primary endpoint in the Phase II study. NCCN currently recommends siltuximab first‐line for iMCD, except for patients considered to have HV histopathology. We investigated whether histopathologic subtype should guide siltuximab treatment decisions. Secondary analyses of clinical trial and real‐world data revealed similar clinical benefit across histopathologic subtypes. Notably, only 18 of 79 patients in the Phase II study were consistently classified into histopathologic subtype by three independent review panels, demonstrating limited reliability to guide treatment decisions. Real‐world data further demonstrate siltuximab's effectiveness in patients considered to have HV (or HyperV). Though histopathology is a critical component for diagnosis, there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
Sperduto, Paul W. , Mesko, Shane , Li, Jing , Cagney, Daniel , Aizer, Ayal A. , Lin, Nancy U. , Nesbit, Eric , Chan, Jason W., Braunstein, Steve , Breen, Will, Brown, Paul D. , Shi, Diana D. , Soliman, Hany , Sahgal, Arjun , Shanley, Ryan , Sperduto, William , Everett, Ashlyn S. , Boggs, Drexell H. , Masucci, Laura , Plichta, Kristin A. , Buatti, John M. , Jain, Supriya , Gaspar, Laurie E., Wu, Cheng–Chia , Wang, Tony J. C. , Bryant, John , Chuong, Michael D. , An, Yi , Chiang, Veronica , Nakano, Toshimichi , Aizer, Ayal , Chan, Jason , Braunstein, Steve , Breen, Will , Brown, Paul D , Shi, Diana , Shih, Helen A , Shanley, Ryan , Lou, Emil , Everett, Ashlyn , Boggs, Drexell H , Buatti, John M , Jain, Supriya , Wang, Tony J C , Chuong, Michael , An, Yi , Chiang, Veronica , Nakano, Toshimichi , Mehta, Minesh P , Lin, Nancy U , Kruser, Tim J. , Lee, Jessica , Kirkpatrick, John P. , Shih, Helen A. , Lou, Emil , Roberge, David , Remick, Jill S. , Aoyama, Hidefumi , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | September 15, 2020 | Volume: 38 | Issue: 32 | Pages: 3773-3784

10.1200/jco.20.01255 | PMID 32931399 Get It

PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).
Outcome of Sacropelvic Resection and Reconstruction Based on a Novel Classification System
Houdek, Matthew T. , Wellings, Elizabeth P. , Moran, Steven L. , Bakri, Karim , Dozois, Eric J. , Mathis, Kellie L. , Yaszemski, Michael J. , Sim, Franklin H. , Rose, Peter S. , Houdek, Matthew T , Wellings, Elizabeth P

Mayo Clinic

Journal of Bone and Joint Surgery | September 15, 2020 | Volume: 102 | Issue: 22 | Pages: 1956-1965

10.2106/jbjs.20.00135 | PMID 32941308 Get It

Background: Sacral tumor resections require a multidisciplinary approach to achieve a cure and a functional outcome. Currently, there is no accepted classification system that provides a means to communicate among the multidisciplinary teams in terms of approach, osseous resection, reconstruction, and acceptable functional outcome. The purpose of this study was to report the outcome of sacral tumor resection based on our classification system. Methods: In this study, 196 patients (71 female and 125 male) undergoing an oncologic en bloc sacrectomy were reviewed. The mean age (and standard deviation) was 49 ± 16 years, and the mean body mass index was 27.2 ± 6.4 kg/m 2 . The resections included 130 sarcomas (66%). The mean follow-up was 7 ± 5 years. Results: Resections included total sacrectomy (Type 1A: 20 patients [10%]) requiring reconstruction, subtotal sacrectomy (Type 1B: 5 patients [3%]) requiring reconstruction, subtotal sacrectomy (Type 1C: 104 patients [53%]) not requiring reconstruction, hemisacrectomy (Type 2: 29 patients [15%]), external hemipelvectomy and hemisacrectomy (Type 3: 32 patients [16%]), total sacrectomy and external hemipelvectomy (Type 4: 5 patients [3%]), and hemicorporectomy (Type 5: 1 patient [1%]). The disease-specific survival was 66% at 5 years and 52% at 10 years. Based on the classification, the 5-year disease-specific survival was 34% for Type 1A, 100% for Type 1B, 71% for Type 1C, 65% for Type 2, 57% for Type 3, 100% for Type 4, and 100% for Type 5 (p < 0.001). Tumor recurrence occurred in 67 patients, including isolated local recurrence (14 patients), isolated metastatic disease (31 patients), and combined local and metastatic disease (22 patients). At 5 years, the local recurrence-free survival was 77% and the metastasis-free survival was 68%. Complications occurred in 153 patients (78%), most commonly wound complications (95 patients [48%]). Following the procedure, 154 patients (79%) were ambulatory, and the mean Musculoskeletal Tumor Society (MSTS93) score was 60% ± 23%. Conclusions: Although resections of sacral malignancies are associated with complications, they can be curative in a majority of patients, with a majority of patients ambulatory with an acceptable functional outcome considering the extent of the resection. At our institution, this classification allows for communication between surgical teams and implies a surgical approach, staging, reconstruction, and potential functional outcomes. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Haploinsufficiency as a disease mechanism in GNB1 ‐associated neurodevelopmental disorder
Schultz‐Rogers, Laura , Masuho, Ikuo , Schmitz, Christopher T., Schwab, Tanya L., Gunderson, Lauren, Pichurin, Pavel N. , Wierenga, Klaas J. , Martemyanov, Kirill A. , Klee, Eric W. , Pinto E Vairo, Filippo, Wierenga, Klaas, Klee, Eric W , Schmitz, Christopher , Vairo, Filippo Pinto e , Clark, Karl J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 14, 2020 | Volume: 8 | Issue: 11 | Pages: No page available

10.1002/mgg3.1477 | PMID 32918542 Get It

Abstract Background GNB1 encodes a subunit of a heterotrimeric G‐protein complex that transduces intracellular signaling cascades. Disruptions to the gene have previously been shown to be embryonic lethal in knockout mice and to cause complex neurodevelopmental disorders in humans. To date, the majority of variants associated with disease in humans have been missense variants in exons 5‐7. Methods Genetic sequencing was performed on two patients presenting with complex neurological phenotypes including intellectual disability, hypotonia, and in one patient seizures. Reported variants were assessed using RNA sequencing and functional BRET/BiFC assays. Results A splice variant reported in patient 1 was confirmed to cause usage of a cryptic splice site leading to a truncated protein product. Patient 2 was reported to have a truncating variant. BRET and BiFC assays of both patient variants confirmed both were deficient in inducing GPCR‐induced G protein activation due to lack of dimer formation with the Gγ subunit. Conclusion Here, we report two patients with functionally confirmed loss of function variants in GNB1 and neurodevelopmental phenotypes including intellectual disability, hypotonia, and seizures in one patient. These results suggest haploinsufficiency of GNB1 is a mechanism for neurodevelopmental disorders in humans.
First-line medication dosing in pediatric refractory status epilepticus
Vasquez, Alejandra , Gaínza‐Lein, Marina , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sannagowdara, Kumar , Tasker, Robert C. , Tchapyjnikov, Dmitry , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Kelley, Sarah A. , Stafstrom, Carl E. , Kossoff, Eric H. , Lewis, Dalila, Stanfield, Tony, Sculier, Claudine , Sansevere, Arnold J. , Sacco, Melissa, Duncan, Abby, McCoy, Jordan, DaSilva-Chiodo, Kathryn, Faist, Robert, Santel, D., LaFay, Victor , Clark, Peggy O., Borror, Sarah, Debs, Andrea, Clohessy, Caitlin, Weber, Amanda , Yuliati, Asri, Luat, Aimée F. , Singh, Azara, Helseth, Ashley , Fernandes, Cecilia, Tran, Linh , McLean, Melissa, Nayak, Anuranjita , Hecox, Kurt, Nallamothu, R. K., Rehborg, Rebecca, Goldstein, David B., Cox, Erin Heinzen, Malone, Colin D., Thornburg, Olivia , Basma, Natasha, Burrows, Brian T., Dyar, Beata, Mishler, Laura, Lee‐Eng, Jacqueline , Streb, Madison, Ganesan, Saptharishi Lalgudi , Huh, Linda , Martic, Nela, Abend, Nicholas S. , Amengual-Gual, Marta, Anderson, Anne, Arya, Ravindra , Brenton, J Nicholas , Farias-Moeller, Raquel, Glauser, Tracy, Goldstein, Joshua L, Guerriero, Rejean M , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J , Payne, Eric T , Tasker, Robert C , Tchapyjnikov, Dmitry , Wainwright, Mark S , Wilfong, Angus, Loddenkemper, Tobias , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Glauser, Tracy A. , Novotny, Edward J. , Bansal, Seema, Habela, Christa Whelan , Aguilar, Cristina Barcia , Santel, Daniel, LaFay, Victor, Turner, David A. , Nallamothu, Rupa, Grinspan, Zachary M. , Appavu, Brian , Hahn, Cecil D.

Mayo Clinic

Neurology | September 11, 2020 | Volume: 95 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000010828 | PMID 32913024 Get It

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Boyle, Shawna, Carlo, Maria I. , Alva, Ajjai , Beckermann, Katy , Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Kyriakopoulos, Christos E. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, Michaelson, M. Dror , Mortazavi, Amir , Nandagopal, Lakshminarayanan , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Somer, Bradley G. , Sosman, Jeffrey A. , Dwyer, Mary A., Motter, Angela D., Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Manley, Brandon J. , Agarwal, Neeraj , George, Saby , Gore, John L. , Haas, Naomi B , Hancock, Steven Lee , Lam, Elaine T. , Madoff, David C. , Pierorazio, Phillip , Plimack, Elizabeth R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 4, 2020 | Volume: 18 | Issue: 9 | Pages: 1160-1170

10.6004/jnccn.2020.0043 | PMID 32886895 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.